Gilron Ian, Watson C Peter N, Cahill Catherine M, Moulin Dwight E
Department of Anesthesiology, Queen's University and Kingston General Hospital, Kingston, Ont.
CMAJ. 2006 Aug 1;175(3):265-75. doi: 10.1503/cmaj.060146.
Neuropathic pain, caused by various central and peripheral nerve disorders, is especially problematic because of its severity, chronicity and resistance to simple analgesics. The condition affects 2%-3% of the population, is costly to the health care system and is personally devastating to the people who experience it. The diagnosis of neuropathic pain is based primarily on history (e.g., underlying disorder and distinct pain qualities) and the findings on physical examination (e.g., pattern of sensory disturbance); however, several tests may sometimes be helpful. Important pathophysiologic mechanisms include sodium-and calcium-channel upregulation, spinal hyperexcitability, descending facilitation and aberrant sympathetic-somatic nervous system interactions. Treatments are generally palliative and include conservative nonpharmacologic therapies, drugs and more invasive interventions (e.g., spinal cord stimulation). Individualizing treatment requires consideration of the functional impact of the neuropathic pain (e.g., depression, disability) as well as ongoing evaluation, patient education, reassurance and specialty referral. We propose a primary care algorithm for treatments with the most favourable risk-benefit profile, including topical lidocaine, gabapentin, pregabalin, tricyclic antidepressants, mixed serotonin-norepinephrine reuptake inhibitors, tramadol and opioids. The field of neuropathic pain research and treatment is in the early stages of development, with many unmet goals. In coming years, several advances are expected in the basic and clinical sciences of neuropathic pain, which will provide new and improved therapies for patients who continue to experience this disabling condition.
由各种中枢和外周神经疾病引起的神经性疼痛尤其成问题,因为它严重、慢性且对简单镇痛药有抗性。这种疾病影响2%至3%的人口,给医疗保健系统带来高昂成本,对患者个人来说具有毁灭性。神经性疼痛的诊断主要基于病史(如潜在疾病和独特的疼痛性质)以及体格检查结果(如感觉障碍模式);然而,有时一些检查可能会有所帮助。重要的病理生理机制包括钠通道和钙通道上调、脊髓兴奋性过高、下行易化以及异常的交感 - 躯体神经系统相互作用。治疗通常是姑息性的,包括保守的非药物疗法、药物和更具侵入性的干预措施(如脊髓刺激)。个体化治疗需要考虑神经性疼痛的功能影响(如抑郁、残疾)以及持续评估、患者教育、安抚和专科转诊。我们提出一种具有最有利风险效益特征的初级保健治疗算法,包括外用利多卡因、加巴喷丁、普瑞巴林、三环类抗抑郁药、5-羟色胺 - 去甲肾上腺素再摄取抑制剂、曲马多和阿片类药物。神经性疼痛的研究和治疗领域尚处于发展初期,有许多未实现的目标。未来几年,预计神经性疼痛的基础和临床科学将取得一些进展,这将为持续遭受这种致残性疾病困扰的患者提供新的、更好的治疗方法。